Jury To Hear Max Planck RNA Interference Patent Suit

Law360, New York (February 11, 2010, 3:53 PM EST) -- A magistrate judge has denied a bid by the Whitehead Institute for Biomedical Research, the Massachusetts Institute of Technology and the University of Massachusetts to strike the Max Planck Institute's demand for a jury in a suit over the licensing of RNA interference patents worth millions.

Magistrate Judge Judith Gail Dein of the U.S. District Court for the District of Massachusetts ruled Wednesday that Max Planck; its licensing arm; and Alnylam Pharmaceuticals Inc., which licenses the patents, are entitled to a jury trial because they have...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.